37.71

2.22% 0.82

After Hours: 37.72 0.010 +0.03%

Nektar Therapeutics (NKTR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Nektar Therapeutics stock is traded at $37.71, with a volume of 590.00K. It is up +2.22% in the last 24 hours and down -43.41% over the past month. Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Previous Close:

$36.89

Open:

$37.15

24h Volume:

590.00K

Relative Volume:

0.27

Market Cap:

$1.29B

Revenue:

$55.63M

Net Income/Loss:

$-158.10M

P/E Ratio:

-4.4785

EPS:

-8.4202

Net Cash Flow:

$-203.94M

1W Performance:

-7.57%

1M Performance:

-43.41%

6M Performance:

-54.69%

1Y Performance:

-33.71%

1-Day Range:

$36.94

$38.74

1-Week Range:

$36.56

$42.38

52-Week Range:

$33.40

$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name

Nektar Therapeutics

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(415) 482-5300

Address

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA

Employee

Twitter

@nektarnews

Next Earnings Date

2026-11-05

Latest SEC Filings

NKTR's Discussions on Twitter

Compare NKTR vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NKTR Nektar Therapeutics	37.71	1.29B	55.63M	-158.10M	-203.94M	-8.4202
VRTX Vertex Pharmaceuticals Inc	508.74	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.35	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.50	53.23B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.30	42.34B	5.76B	514.49M	1.10B	4.4813

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-12-26	Initiated	Leerink Partners	Outperform
Oct-12-26	Initiated	UBS	Neutral
Oct-09-26	Initiated	Raymond James	Mkt Perform
Aug-21-26	Resumed	JP Morgan	Neutral
Jul-22-26	Initiated	Canaccord Genuity	Buy
Mar-24-26	Initiated	Wedbush	Neutral
Mar-17-26	Initiated	TD Cowen	Buy
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy
Jun-24-25	Reiterated	BTIG Research	Buy
Jun-24-25	Reiterated	H.C. Wainwright	Buy
Apr-11-25	Upgrade	Jefferies	Hold → Buy
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform
Jan-08-25	Initiated	B. Riley Securities	Buy
Dec-10-24	Initiated	H.C. Wainwright	Buy
Nov-04-24	Initiated	Piper Sandler	Overweight
Sep-30-24	Resumed	BTIG Research	Buy
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold
Feb-24-23	Downgrade	Jefferies	Hold → Underperform
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold
Apr-18-22	Downgrade	Goldman	Neutral → Sell
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-15-22	Downgrade	Mizuho	Buy → Neutral
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-14-22	Downgrade	Stifel	Buy → Hold
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy
Sep-10-21	Initiated	BofA Securities	Neutral
Jun-28-21	Upgrade	Stifel	Hold → Buy
May-18-21	Resumed	Goldman	Neutral
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold
Sep-14-20	Initiated	JP Morgan	Neutral
Jun-10-20	Downgrade	CFRA	Hold → Sell
May-12-20	Reiterated	H.C. Wainwright	Neutral
Apr-22-20	Initiated	The Benchmark Company	Buy
Mar-30-20	Upgrade	Goldman	Sell → Neutral
Mar-04-20	Initiated	Barclays	Overweight
Feb-03-20	Upgrade	Mizuho	Neutral → Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-08-19	Downgrade	Goldman	Buy → Sell
Aug-09-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-09-19	Downgrade	Jefferies	Buy → Hold
Aug-09-19	Downgrade	Mizuho	Buy → Neutral
Mar-15-19	Initiated	SVB Leerink	Mkt Perform
Dec-13-18	Initiated	Goldman	Buy
Jun-11-18	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-04-18	Reiterated	H.C. Wainwright	Buy
Apr-20-18	Initiated	Seaport Global Securities	Buy
Apr-13-18	Resumed	Piper Jaffray	Overweight
Apr-06-18	Reiterated	Mizuho	Buy
Apr-02-18	Resumed	H.C. Wainwright	Buy

View All

Nektar Therapeutics Stock (NKTR) Latest News

Oct 13, 2026

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC) - The Globe and Mail

Oct 13, 2026

Oct 12, 2026

Nektar Therapeutics Initiated at Neutral by UBS - Moomoo

Oct 12, 2026

UBS Initiates Nektar Therapeutics(NKTR.US) With Hold Rating, Announces Target Price $53 - Moomoo

Oct 12, 2026

Leerink Highlights Nektar Therapeutics (NKTR) as Top Emerging Te - GuruFocus

Oct 12, 2026

Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology - Seeking Alpha

Oct 12, 2026

Nektar Therapeutics Price Target Announced at $53.00/Share by UBS - Moomoo

Oct 12, 2026